At a time when demand for intensive care units (ICU) is at an unprecedented high, the rapid diagnosis of disease has never been more important.
According to EU recommendations, timely and accurate COVID-19 laboratory testing is an essential part of the management of COVID-19. Testing helps fight the pandemic, supports decisions on infection control strategies and patient management at healthcare facilities, and detects asymptomatic cases that could spread the virus further if not isolated.i
COVID-19 may be accompanied by a secondary bacterial or viral infection in the immunocompromised individual. Rapid diagnosis is critical to determine the correct course of treatment.
Early testing, diagnosis and intervention significantly increase the likelihood of an individual’s recovery – where a gain in minutes or hours can mean the difference between life and death. Reducing the need for prolonged and often invasive ICU treatment, the chance of recovery is greater and vital resources are available more quickly for the next patient.
With clinical laboratories across the globe under intense pressure to deliver increased demand for test results, Bruker’s molecular and diagnostic systems offer a rapid response. A swift and accurate diagnosis establishes the correct course of action straight away, which, ultimately means fewer lives will be lost.